Brokers Set Expectations for RVMD Q3 Earnings

Revolution Medicines, Inc. (NASDAQ:RVMD) – Analysts at Brookline Capital Markets issued their Q3 2026 earnings per share estimates for Revolution Medicines in a research report issued on Thursday, October 15th. Brookline Capital Markets analyst L. Cann expects that the company will post earnings of ($2.36) per share for the quarter. Brookline Capital Markets currently has a “Buy” rating and a $318.00 target price on the stock. The consensus estimate for Revolution Medicines’ current full-year earnings is ($8.93) per share. Brookline Capital Markets also issued estimates for Revolution Medicines’ Q4 2026 earnings at ($1.94) EPS.

A number of other equities research analysts have also issued reports on RVMD. Bank of America increased their price objective on shares of Revolution Medicines from $225.00 to $265.00 and gave the company a “buy” rating in a report on Monday, September 21st. TD Cowen reissued a “buy” rating on shares of Revolution Medicines in a report on Thursday, October 8th. Mizuho upped their target price on shares of Revolution Medicines from $185.00 to $215.00 and gave the stock an “outperform” rating in a research report on Monday, July 6th. Truist Financial raised their target price on shares of Revolution Medicines from $240.00 to $241.00 and gave the company a “buy” rating in a research note on Monday. Finally, HC Wainwright lifted their price target on shares of Revolution Medicines from $195.00 to $280.00 and gave the company a “buy” rating in a report on Thursday, August 27th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Revolution Medicines has a consensus rating of “Moderate Buy” and an average target price of $242.60.

Revolution Medicines Price Performance

NASDAQ RVMD opened at $182.15 on Tuesday. The stock’s 50 day moving average is $202.72 and its 200 day moving average is $174.59. The company has a debt-to-equity ratio of 0.40, a current ratio of 11.38 and a quick ratio of 11.38. Revolution Medicines has a 12 month low of $52.48 and a 12 month high of $224.31.

Revolution Medicines (NASDAQ:RVMD) last released its earnings results on Wednesday, August 5th. The company reported ($3.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.04) by ($1.02). During the same period in the previous year, the firm posted ($1.31) earnings per share.

Institutional Investors Weigh In On Revolution Medicines

Several institutional investors have recently modified their holdings of the stock. Burkett Financial Services LLC purchased a new stake in Revolution Medicines during the 3rd quarter valued at $27,000. Contravisory Investment Management Inc. purchased a new position in Revolution Medicines during the second quarter worth $32,000. ABS Investment Management LLC purchased a new position in Revolution Medicines during the second quarter worth $337,104,000. Johnson Financial Group Inc. bought a new position in Revolution Medicines during the second quarter valued at $37,000. Finally, Mather Group LLC. bought a new position in Revolution Medicines during the third quarter valued at $41,000. 94.34% of the stock is owned by institutional investors.

Insider Transactions at Revolution Medicines

In other Revolution Medicines news, Director Elizabeth Anderson sold 10,143 shares of the stock in a transaction on Tuesday, September 22nd. The shares were sold at an average price of $193.04, for a total transaction of $1,958,004.72. Following the completion of the transaction, the director owned 4,333 shares in the company, valued at $836,442.32. This trade represents a 70.07% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Lorence Kim sold 56,000 shares of the business’s stock in a transaction dated Monday, August 31st. The stock was sold at an average price of $203.24, for a total transaction of $11,381,440.00. Following the completion of the sale, the director owned 17,090 shares in the company, valued at approximately $3,473,371.60. This trade represents a 76.62% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 290,991 shares of company stock valued at $59,422,765 in the last 90 days. Company insiders own 7.60% of the company’s stock.

About Revolution Medicines

Revolution Medicines, Inc is a clinical-stage biopharmaceutical company focused on developing targeted therapies for patients with RAS-mutant cancers. The company’s research platform is designed to discover and develop medicines that inhibit RAS proteins, which play a central role in the growth and spread of many cancers and have historically been difficult to target.

Its investigational pipeline includes RAS(ON) inhibitors and other precision oncology candidates, including daraxonrasib (RMC-6236), a pan-RAS inhibitor being evaluated in multiple solid tumors, as well as programs directed at specific mutations such as KRAS G12C and KRAS G12D.